No Clinically Significant Drug Interaction Between Azithromycin and Rosuvastatin
Azithromycin and rosuvastatin can be safely co-administered without dose adjustments or special precautions, as there is no established pharmacokinetic or pharmacodynamic interaction between these two medications.
Pharmacokinetic Rationale
The absence of interaction is explained by their distinct metabolic pathways:
Rosuvastatin is minimally metabolized by CYP450 enzymes and is primarily eliminated unchanged. Its disposition depends on transporter proteins, particularly OATP1B1, P-glycoprotein (P-gp), and BCRP 1.
Azithromycin does not significantly inhibit CYP3A4 (unlike other macrolides such as erythromycin or clarithromycin) and does not meaningfully affect the transporter proteins involved in rosuvastatin metabolism 1.
The FDA drug label for rosuvastatin explicitly lists erythromycin as causing a 20% decrease in rosuvastatin exposure (AUC ratio 0.8), demonstrating that even macrolides that do interact have minimal clinical impact 1. Notably, azithromycin is not listed among the numerous drugs that interact with rosuvastatin in the comprehensive FDA interaction tables 1.
Evidence Regarding Azithromycin-Statin Interactions
While case reports exist of azithromycin-associated rhabdomyolysis with CYP3A4-metabolized statins (simvastatin, atorvastatin, lovastatin) 2, 3, these interactions are mechanistically distinct from rosuvastatin:
- The reported cases involved statins heavily dependent on CYP3A4 metabolism 2, 3
- One case involved a patient with SLCO1B1 genetic polymorphism affecting statin uptake, representing a rare "dual-hit" mechanism 3
- Rosuvastatin is not subject to CYP3A4 metabolism, eliminating this interaction pathway
Clinical Recommendation
Co-prescribe azithromycin and rosuvastatin without modification to either medication's dosing. No additional monitoring beyond standard statin surveillance is required. This combination does not warrant the precautions necessary for rosuvastatin when combined with known interacting agents such as cyclosporine (7-fold AUC increase), gemfibrozil (1.9-fold increase), or protease inhibitors 1.
Important Distinction
Do not confuse this favorable interaction profile with other macrolides. Erythromycin and clarithromycin are potent CYP3A4 inhibitors and require different considerations when combined with CYP3A4-metabolized statins.